New study to track cancer risk in rare genetic condition

NCT ID NCT05630105

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 22 times

Summary

This study follows 430 people with Cowden's disease (a PTEN gene mutation) to see how often they develop cancer. Researchers will track any cancers, especially breast and thyroid, over time. The goal is to better understand cancer risks in this group to improve future monitoring and care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PTEN GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • 1-CHU Amiens

    Amiens, France

  • 10-CHU Colmar

    Colmar, France

  • 11-CHU Dijon

    Dijon, France

  • 12-CHU Grenoble

    Grenoble, France

  • 13a-AP-HP Hôpital Avicenne

    Paris, France

  • 13b-AP-HP Hôpital Saint-Antoine

    Paris, France

  • 13c-APH-HP Hôpital Salpétrière

    Paris, France

  • 13d-AP-HP Hôpital Trousseau

    Paris, France

  • 13e-AP-HP Hôpital Saint-Louis

    Paris, France

  • 13f-AP-HP Hôpital Robert Debré

    Paris, France

  • 14-Institut Curie

    Paris, France

  • 15-Institut Gustave Roussy

    Villejuif, France

  • 16-CHU Lille

    Lille, France

  • 17-CHU Limoges

    Limoges, France

  • 18a-Hospices Civils Lyon - Lyon Est

    Lyon, France

  • 18b-Hospices Civils Lyon - Lyon Sud

    Lyon, France

  • 19-AP-HM Hôpital de la Timone

    Marseille, France

  • 2-CHU Angers

    Angers, France

  • 20-CHU Montpellier

    Montpellier, France

  • 21-CHU Nantes

    Nantes, France

  • 22-CHU Nice

    Nice, France

  • 23-CHU Nîmes

    Nîmes, France

  • 24-CHU Poitiers

    Poitiers, France

  • 25-Institut du Cancer Courlancy

    Reims, France

  • 26-Centre Eugène Marquis

    Rennes, France

  • 27-CHU Rennes

    Rennes, France

  • 28-CHU Saint-Etienne

    Saint-Etienne, France

  • 29-Institut Strauss

    Strasbourg, France

  • 3-ICO Angers et Nantes

    Angers, France

  • 30-CHU Toulouse

    Toulouse, France

  • 31-CHU Tours

    Tours, France

  • 32-Centre Antoine Lacassagne

    Nice, France

  • 33-Institut Paoli Calmettes

    Marseille, France

  • 34-CH Valence

    Valence, France

  • 35-CHU Rouen

    Rouen, France

  • 36-CH Le Mans

    Le Mans, France

  • 37-CH Niort

    Niort, France

  • 38-CHU Guadeloupe

    Pointe à Pitre, France

  • 4-CHU Besançon

    Besançon, France

  • 40-CHU Troyes

    Troyes, France

  • 5-CHU Bordeaux

    Bordeaux, France

  • 6-Institut Bergonié

    Bordeaux, France

  • 7-CHU Brest

    Brest, France

  • 8-Centre François Baclesse

    Caen, France

  • 9-CH Métropole Savoie Chambéry

    Chambéry, France

Conditions

Explore the condition pages connected to this study.